18.84 USD
↘ 0.31 (1.62%)AT CLOSE (11:59 AM EDT)
Viridian Therapeutics, Inc. Common Stock
VRDNNASDAQ • USD
18.77
↘ 0.08 (0.40%)
POST MARKET (AS OF 07:10 PM EDT)
Post Market
AS OF 07:10 PM EDT
18.77
↘ 0.08 (0.40%)
Market: CLOSED
Open?$18.56
High?$19.25
Low?$18.44
Prev. Close?$19.15
Volume?3.1M
Avg. Volume?2.0M
VWAP?$18.83
Rel. Volume?1.54x
Bid / Ask
Bid?$16.31 × 100
Ask?$21.46 × 100
Spread?$5.15
Midpoint?$18.88
Valuation & Ratios
Market Cap?1.9B
Shares Out?102.2M
Float?51.9M
Float %?63.6%
P/E Ratio?N/A
P/B Ratio?2.67
EPS?-$2.76
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?12.65Strong
Quick Ratio?12.65Strong
Cash Ratio?3.00Strong
Debt/Equity?0.12Low
ValuationFAIRLY VALUED
Score67/100
P/E?N/A▾
P/B?2.67CHEAP▾
P/S?27.18HIGH▾
P/FCF?N/A▾
EV/EBITDA?-5.0CHEAP▾
EV/Sales?25.37HIGH▾
Returns & Efficiency
ROE?-39.0%WEAK▾
ROA?-31.3%WEAK▾
Cash Flow & Enterprise
FCF?$-276886000
Enterprise Value?$1.8B
Related Companies
Loading...
News
Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Employees
252
Market Cap
1.9B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-06-18
Address
221 CRESCENT STREET
WALTHAM, MA 02453
Phone: 617.272.4600
WALTHAM, MA 02453
Phone: 617.272.4600